Results 221 to 230 of about 92,046 (305)

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years [PDF]

, 2017
Dehner, Louis P, et al,
core   +1 more source

Comprehensive assessment of unfolded protein response and its association with tumor progression in pan‐cancer

iMetaOmics, Volume 3, Issue 1, March 2026.
Schematic of the study design. In this study, we developed a comprehensive unfolded protein response (UPR) gene signature and applied it to systematically characterize the UPR landscape across multiple cancer types. By integrating bulk and single‐cell transcriptomic data, we revealed substantial inter‐ and intra‐tumoral heterogeneity in UPR activity ...
Xinyu Yang, Faming Zhao, Jing Yang, Xinran Xia, Liwei Chen, Peng Zeng, Liang Chen, Yanxia Hu, Xia Sheng   +8 more
wiley   +1 more source

Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial Cancer. [PDF]

Eur Urol Open Sci
Haas M, Mayr R, Sikic D, Wullich B, Klümper N, Erben P, Wirtz R, Bolenz C, Roghmann F, Stöhr R, Bahlinger V, Hartmann A, Burger M, Breyer J, Eckstein M, BRIDGE Consortium e.V.   +15 more
europepmc   +1 more source

RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets

MedComm, Volume 7, Issue 3, March 2026.
RNA regulatory networks play a crucial role in the initiation and progression of cancer through various modes of RNA interactions. Notably, circulating RNAs have emerged as potential biomarkers, while targeted interventions in RNA regulatory networks facilitate precise therapeutic strategies. ABSTRACT Cancer is a global health challenge. The initiation
Xuan Yin, Zengkan Du, Shuya Jiang, Yan Liao, Changli Wang, Jiaqi Li, Haoling Zhang, Ting‐Ting Wei, Wangzheqi Zhang, Zui Zou   +9 more
wiley   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Early Cancer Detection: What's Going on and What's Next

MedComm, Volume 7, Issue 3, March 2026.
Multicancer early detection (MCED) platforms have emerged as a promising strategy for the safe and effective early detection of multiple cancer types, with the potential to reduce metastatic burden and improve clinical outcomes, particularly for aggressive malignancies that lack effective population‐level screening.
Emma Di Carlo
wiley   +1 more source

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab. [PDF]

Sci Rep
Incorvaia L, Scagliarini S, Marques Monteiro FS, Takeshita H, Tapia JC, Gandur Quiroga MN, Lam E, Tural D, Popovic L, Campos-Gomez S, Zucali PA, Mota A, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Abahssain H, Galosi AB, Badalamenti G, Kopecky J, Bamias A, Landmesser J, Ansari J, Calabrò F, Massari F, Buti S, Bellmunt J, Santoni M.   +29 more
europepmc   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins. [PDF]

Int J Urol
Kobayashi G, Hayashi T, Sekino Y, Ikeda K, Nakahara H, Kobatake K, Goto K, Taniyama D, Kuraoka K, Akabane S, Niitsu H, Hinoi T, Sentani K, Hinata N.   +13 more
europepmc   +1 more source

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

Med Research, Volume 2, Issue 1, Page 157-180, March 2026.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang, Wenhao Xu, Weiqing Lu, Yingxuan Lin, Luoxi He, Zonglin Lv, Yiliyaer Nuerrula, Zouting, Zhen Zhang, Hailiang Zhang, Xuejun Ma   +10 more
wiley   +1 more source